RYK

2022-03-18   Roberto Brusamolino , Alessandro Beghini 

University of Milan

Abstract

{RYK} (receptor-like tyrosine kinase) gene belongs to the RTK (receptor tyrosine kinase) superfamily and functionally belongs to the group of Wnt ligand-binding receptors involved in the canonical and non-canonical {Wnt signaling}. {RYK} encodes a pseudokinase involved in the modulation of a branch of the {Wnt pathway}, whose signals contribute to organogenesis (prevailing impact on axon outgrowth and axon guidance function) and to crucial post-development conditions (e.g.cell survival, migration, polarization and chemotaxis). Tissue expression is broad and has both lineage- and stage-specific patterns. As for the pathology gene disruption causes early lethality characterized by cardiovascular and cranio-facial maldevelopment and {RYK} mutations are strongly suspected as the causative factor for non-syndromic cleft-lip and palate. In a truly complex general framework that is still today affected by large areas of uncertainty, this gene, as many other members of the large RTKs group, has been correlated to many neoplastic nosological entities (e.g. gastric and ovarian cancer, {acute myeloid leukemias}, melanoma and glioblastoma) and few non-neoplastic conditions (e.g. rheumatoid arthritis).

Keywords
RYK, Receptor-like tyrosine kinase, Pseudokinase, Growth Factor Receptor Protein Tyrosine Kinase

DNA/RNA

Description

NOTE: First cloning of RYK was performed in 1992, 1 with a PCR-based screen procedure (homology screen with primers based on highly conserved motifs common to all members of the protein tyrosine kinase [PTK] family), aimed to discover novel receptor tyrosine kinases. The new PTK-related molecule, RYK, was identified from murine peritoneal macrophage cDNA. The RYK sequence was characterized by unusual variations on the ordinarily highly conserved elements of the PTK family, prompting a specialized role in signal transduction within the cell. The human homologue of mouse Ryk has been cloned from a human hepatoma cDNA library by cross-species hybridization based on probing the tumor library with the mouse Ryk cDNA. 2 Derailed and LIN-18 are orthologs of RYK respectively in Drosophila and Caenorhabditis.  GENE_NAME: RYK (receptor-like tyrosine kinase or related to receptor tyrosine kinases). CHROMOSOMAL LOCALIZATION: the RYK localization was determined by FISH analysis on normal human metaphase spreads and was shown to map to 3q22.2. 3


Figure 1: RYK localization by FISH

RYK localization on normal human metaphase with RTK15-EcoRV linearized clone 15.5BX3 as a probe. Image adapted from 3

LOCAL ORDER: gene sequence starts at 134157134 and ends at 134250744 bp from pter of the chromosome 3 (according to hg38). Source: Ensembl (RYK-208) ENST00000620660.4


Figure 2 Chromosomal band localization of RYK

RYK gene maps to 3q22.2

STRAND: reverse (-)

SIZE: 93611bp (including UTRs)

CODING REGION (source UCSC): Position: chr3:134,158,153-134,250,654. Size: 92502 bp.

RYKDNA FULL EXON-INTRON SEQUENCE: see the following internet address http://www.ensemble.org/id/ENSG00000163785 .

GENOMIC TOPOGRAPHY AND EXON-INTRON DISTRIBUTION OF RYK GENE: see Figure 3 modified from NCBI.


Figure 3. RYK genomic topography and  Exon-Intron distribution


Transcription

TRANSCRIPT LENGTH: 2942 bps (Source: Ensembl RYK-208 ENST00000620660.4)

CODING EXON COUNT: 15 (TOTAL EXON COUNT: 15)

TRANSLATION LENGTH: 610 residues (Source: Ensembl RYK-208 ENST00000620660.4)

TRANSCRIPT VARIANTS: alternative splicing results in multiple transcript variants encoding distinct isoforms: this gene has 9 transcripts (splice variants) and 2 main isoforms. Source ENSG00000163785


Pseudogene

Probing the genome by in situ hybridization two RYK loci (Ryk-1 locus and Ryk-2 locus) were identified on 3q22 (RYK gene) and on 17q13.2 (RYKP1 [RYK pseudogene 1 ]) ( PMID: 8386829 ; PMID: 7613029).The 3’ untranslated region human RYK cDNA-derived probe detects only the 3q22 locus and gives evidence that this is the only locus that encodes a functional protein in humans. The possibility has been proposed (PMID: 10454588) that a hypothetical product of the RYK2 locus (pp75) represents the Ryk-2 locus receptor and could be the kinase-active partner of RYK gene via a heterodimerization mechanism. However until now the cDNA for Ryk-2 has not been isolated.

Proteins

Description

From 58 known human receptor tyrosine kinases (RTKs), 8 are classed as pseudokinases 4 and four protein of this group are involved in Wnt signalling: RYK, ROR1, ROR2, PTK7. RYK, as well as other pseudokinases, has substitutions in conserved motifs and lacks both kinase activity and ATP binding ability.

PROTEIN SYMBOL: P34925-RYK_HUMAN (UniProtKB/Swiss-Prot).

RECOMMENDED NAME: Tyrosine-protein kinase RYK (UniProtKB/Swiss-Prot).

SIZE: 607 amino acids

MOLECULAR MASS: 67815 Da

STRUCTURE: see  https://www.uniprot.org/uniprot/P34925/protvista



Figure 4: Comparison between several examples of human RTK pseudo kinases in relation to the different protein domains composing them, located in the extracellular region (above), membrane and intracellular region(below). Domains are listed in the legend: RYK has 2 main functional domains: 1-pseudokinase (red), 2- Wnt Inhibitory Factor (WIF) domain.

1- Wnt-inhibitory factor-1 like domain (WIF1): (related to protein location 63>196). WIF1 sequence codes for a protein extracellular domain in metazoan RYK receptor tyrosine kinases. WIF-1 binds to Wnts ligands and inhibits their activity.

2- Pseudokinase domain of RYK (related to protein location 326 > 606). RYK pseudokinase sequence codes for an extracellular region with two leucine-rich motifs, a transmembrane segment, and an intracellular inactive pseudokinase domain, which shows similarity to tyrosine kinases but lacks crucial residues for catalytic activity and ATP binding.

RYK belongs to the RTK family, wich includes transmembrane glycoproteins typically endowed with an N-terminal extracellular ligand-binding domain and a C-terminal intracellular tyrosine kinase domain. 1

As shown in figure 4 RYK shares with all other members of the RTKs family a hydrophobic transmembrane domain (lenght: 28 aa., from 187 to 215) and an intracellular kinase domain with all typical expected features. 5

However, there are strong structural differences with respect to the family to which RYK protein belongs, represented by a very short extracellular domain (183 aa) and an unusual kinase domain. RYK extracellular domain lacks typical features of all other RTKs (e.g.immunoglobulin-like domains or cysteine-rich domains ) but is equipped with 2 LRMs (Leucine-rich motifs) that are part of a WIF-type Wnt binding domain. In turn the intracellular kinase domain while showing a clear tyrosine specificity is almost unique in the family showing a sequence substitution (aspartate-asparagine-alanine [D-F-G motif] instead of aspartate-phenylalanine-glycine [D-N-A motif] where the Phe and Gly residues in the DFG motif of the activation domain are essential for catalytic activity of RTKs) in a key position for the catalytic activity and for the ATP binding. 6

Figure 5 shows a structural comparison between RYK and its catalytically active counterpart IRK (insulin receptor kinase); RYK in its activation loop configuration closely resemble inactive IRK. Structural elements in the RTK pseudokinase domains are not significantly more rigid than in catalytically active counterparts such as IRK. It's possible for the pseudokinases to keep conformational switching-based regulatory mechanisms typical of active kinases. RYK and the other members of the group of Wnt-binding pseudokinase ROR1,ROR2, PTK7 being no more static than typical kinases, could show dynamic characteristics very similar to those of IRK. RYK pseudokinase domains display conformational dynamics similar to those of IRK, despite mimicking an ATP-bound state which could control scaffolding functions in signaling. The RTK pseudokinases are likely to resemble canonical protein kinases such as IRK in their capabilities to undergo transitions between active and (family-specific) inactive conformations. 4 Despite their apparent lack of catalytic activity these pseudokinases are essential signaling molecules.


Figure 5: Close-up of residues surrounding the ATP-binding site for active and inactive IRK-insulin receptor kinase (black) and for RYK. AMP-PNP (analog of ATP) is solid when seen in the relevant crystal structure and transparent when not. Note the D-N-A motif instead of the canonical D-F-G. Adapted from 4


Expression

RYK is expressed in many different tissues both during development and in adults, suggesting a widespread function.


Figure 6 RYK gene expression in various tissues http://biogps.org/#goto=genereport&id=6259


Localisation

RYK is located on the cell membrane as a single-pass type 1 membrane protein (protein spanning the membrane once, with its N terminus on the extracellular side of the membrane and removal of its signal sequence)

Function

Ryk is a widely expressed member of the general PTK family, with all of the features of a growth factor receptor, and more specifically is an atypical member of the family of growth factor receptor protein tyrosine kinases with structural differences from other members in the activation and nucleotide binding domains already mentioned above. It belongs to a subfamily whose members (the Wnt-binding ROR1ROR2, PTK7 and few others) do not appear to be regulated by phosphorylation in the activation segment. 1 Ligand stimulation of the RYK receptor results in activation of the mitogen-activated protein kinase (MAPK) pathway. 6 In 1999, RYK’s function emerged from the fruitfly, Drosophila melanogaster, in which the RYK ortholog (Derailed) was found to be a chemorepulsive on the axon growth. 7 The Derailed ligand was identified in 2003 as Wnt5 8 and in 2009 Wnt5a/Ryk interactions were recognized as necessary for chemorepulsive axon guidance in the developing mammalian brain and spinal cord 9. In vertebrates, more diverse roles are emerging for RYK in a range of neurodevelopmental processes; RYK is important for establishing planar polarity during neural tube formation. 10 It is as well essential in skeletal (e.g.osteoclast differentiation), 11 craniofacial, and cardiac development. Undoubtedly, given these premises, RYK is involved in signal transduction despite its lack of kinase activity. Derailed, the Drosophila RYK ortholog, contains an extracellular Wnt-interacting WIF domain with ability to bind the fruitfly D-Wnt-5 protein. 8 This indicates Derailed is a D-Wnt-5 receptor. In 2005 proof has been given that in mammals too (mouse) RYK is a high-affinity receptor for Wnt5a. 12 Wnt5a is the ligand and Ryk is the receptor binding it with its extracellular WIF domain. 13 Also the other pseudokinases RORs and PTK7 are receptors or co-receptors for WNTs but RYK is special as the only one having a WIF (for WNT-Inhibitory Factor) as the binding motif. RORs have an extracellular cysteine-rich domain (CRD) related to that seen in FZDs and PTK7 has a multiple immunoglobulin-like domain (see FIG. 7). The correlations between WNTs and their ligands are complex as suggested by the fact that RYK appears to form WNT-dependent complexes with FZDs. 14 The kinase domain lacks enzymatic activity but it is peculiar in the fact of being cleaved by a gamma-secretase with a product that migrates to nucleus. This could be an alternative way to regulate Wnt-linked signaling. Recent developments confirm that WNTs cross-link RTK pseudokinase co-receptors into signaling complexes with FZDs, within which they might allosterically regulate other key components. 15 The complexity of Wnt signaling was well known as well as the concept that Wnt family are key regulators of pivotal developmental processes (embryonic patterning, specification of cell fate, determination of tissue polarity, development of mammalian central nervous system). Three interconnected signaling pathways (canonical, noncanonical, and Wnt/calcium pathways) are known for Wnts ligand system and each of them is activated by a subset of receptors, configuring the Wnt signaling as highly regulated at the level of ligand–receptor interactions. RYK associates molecularly to FZD receptors and can modulate canonical (beta-catenin dependent) and non-canonical (beta-catenin independent) pathways. 16


Figure 7 Extracellular domains of WNTs-related pseudokinase

RYK with respect to the other Wnt-binding pseudokinases is characterized by the exclusive extracellular WIF domain.


Homology

A few years after the discovery of RYK extensive cross-species reactivity of a mouse RYK kinase subdomain probe demonstrated that RYK and related family members encode a class of widely conserved proteins. 17 210 orthologues and 53 paralogues are known (ENSG00000163785). 354 organisms have orthologs with human gene RYK. The RYK gene is conserved in chimpanzee, dog, cow, mouse, rat, chicken, zebrafish, fruit fly, mosquito, Caenorhabditis elegans and frog.

Mutations

Mutations

Very little is known about mutations of pathogenetic significance. The only observation reported in the literature concerns a survey carried out on a large sample (354) of Vietnamese, Japanese, and Caucasian patients with cleft lip and/or palate (CL/P) gathered in a group of 1647 tests comprising patient relatives and normal adult controls. 18 Only 1 out of the patient samples tested harbored a RYK missense mutation, 1355G.A (Y452C). Moreover, the unaffected father of the patient carried the same mutation. The effect of this mutation could be a decrease in the gene function and this mutation in RYK may explain a small subset of CL/P.

Implicated in

Entity name(s)
Note: The difficulty of studying the impact of the RYK gene on human pathology is strictly connected to the great complexity of the molecular circuits in which it is inserted. RYK is in fact a receptor-coreceptor related to WNT signaling, whose dominant feature is the large number of members that compose it and the intricate network of interactions that underlies the delicate phenomena of modulation of signaling activity. Being an integral part of such a complex molecular network, it is difficult to isolate the effects of RYK at the cellular and tissue level, being at all times the latter in dynamic balance with a number of interactions with other molecules involved in the transduction of signals from outside the cell. What is certain is that it is an evolutionarily conserved gene, with multi-tissue expression, importance in development processes and involved in crucial cellular functions. Therefore it is not surprising that links have been found between RTK pseudokinases, the enzymic subfamily to which RYK belongs, and several pathological conditions, mainly oncological. In recent years intense effort has been produced in developing therapeutic approaches to inhibit their signaling functions and also RYK, albeit to a lesser extent than other members of his family, has been the subject of this type of investigation. 19,Entity name: Leukemia In bone marrow RYK has a higher level of expression in the stromal cell compartment rather than the hematopoietic cells and is responsible of the fine-tuning of the Wnt signaling optimizing the responses of hematopoietic stem cells (HSC) to environmental physiologic and pathologic stimuli. WNT5A and WNT3A are pivotal ligands for bone marrow function and Wnt signaling dysregulation is observed in stromal cells of leukemic bone marrow. 16 RYK collaborates with WNT5A in activating non-canonical Wnt signaling and keeping in a state of quiescence the HSC. RYK decreases HSPC apoptosis after 5-FU (fluorouracil) and total body irradiation, favoring their survival and decreasing the ROS (reactive oxygen species) levels. This effect results in an advantage for cell in better surviving myeloablative stress. 20 RYK knock-out in HSC of mouse fetal liver reduces cell quiescence inducing proliferation-mediated apoptosis and impaired self-renewal. 21,21 Collectively these data suggest that RYK receptor mediates the effect of WNT5A on HSC quiescence and hematopoietic repopulation, that are improved while the level of ROS is reduced. Leukemia-derived cell lines (myeloblast, T and B lines) were analysed for RYK expression by cytofluorimetry. RYK receptor has been found highly expressed in leukemia cells, mainly in those positive for immaturity markers (CD33, CD13, CD7, CD117). This paves the way for the use of RYK as diagnostic marker and therapy target. 22 RYK-associated PCP (planar cell polarity) pathway and Rho-dependent signaling are involved in pathogenesis of CLL (chronic lymphocytic leukemia). CLL shows also occasionally mutations of RYK. Lastly RYK is overexpressed in leukemia–derived cell lines and in bone marrow and peripheral neoplastic cells of leukemic patients. At the moment RYK targeted therapies are not significantly useful. 23,Entity name: Breast cancer Wnt signaling is involved in the processes of breast cancer proliferation and metastasis (e.g.microenvironment, cell stemness, phenotype shaping). Beta-catenin dependent and independent Wnt pathways differently affect the breast cancer fate. It is a very studied subject in an effort to identify inhibitors of major molecular targets. 24 In all main subtypes of breast cancer RYK and WNT5A are found under-expressed. Heterozygous loss of WNT5A was observed in cancer patients with shorter survival. Basal TICs (tumor-initiating cells) are suppressed in their growth by the luminal cell-produced WNT5A. This happens in a TGFBR (Transforming Growth Factor Beta Receptor)-dependent manner (WNT-5A is a downstream effector of TGFBR mediating its suppressive effect on mammary carcinogenesis). In the presence of RYK, WNT5A induces in the neoplastic basal cells a TGFBR /SMAD2 module with growth suppression effect. RYK is able to form a complex with TGFBR /SMAD2 leading to the phosphorylation and activation of SMAD2. This paracrine control of the luminal cells on the basal cells (luminal-basal crosstalk) is observed in both mammary gland development and carcinogenesis and offers the possibility of targeting therapeutically the breast cancer. 25,Entity name: Ovarian cancer RYK is overexpressed in 25% of ovarian cancer without correlation with istological type and tumor stage or grade. RYK-mRNA is minimally represented in the normal ovarian epithelium or stroma. In benign and borderline tumors, increased signal strength from the mRNA in the stroma was observed with minimal epithelial expression. 3 Conversely malignant epithelial cells and tumoral blood vessels (endothelial and smooth muscle layers of arteries and veins) are both manifesting overexpression and when this happens overall survival and progression-free survival are significantly reduced. Despite the fact that overexpression experimentally induced is able to produce neoplastic transformation in vitro and tumor formation in vivo it is not possible to determine whether the RYK increase in human ovarian cancer is a primary or secondary event. The presence of RYK in neoplastic blood vessels and the analogy with other angiogenic growth factors/ receptor in tumors makes the second hypothesis more probable. 26,Entity name: Glioblastoma In human glioma, the expression of WNT5A is higher than in normal brain tissue. Furthermore, over-expressed WNT5A promotes the proliferation of neoplastic glial cell lines in vitro. WNT5A signals are mediated by FZD-2, FZD-3, FZD-4, FZD-5, FZD-6 FZD-7 AND FZD-8 to regulate cellular functions. Other co-receptors of Wnt-5a are Ror1/2 and receptor-like tyrosine kinase (RYK). Of this array of receptors Fz-2 and RYK are the two only upregulated in glioblastoma. WNT-5A and RYK regulate MMP2 (matrix metalloproteinase 2). FZD-2 shows a selective role in WNT5A-dependent cellular migration. All in all, considering that MMPs are the matrix degrading proteinases that digest the extracellular matrix (ECM), promoting tumor invasion and extravasation, the importance of FZD-2 and RYK for the WNT5A-dependent invasive activity of glioblastoma cells is demonstrated. Moreover, the expression of WNT5A, FZD2, RYK and MMP2 correlate with WHO grade of glioblastoma. Therefore WNT-5A shows no effect on the proliferation of glioma cells but works as a ligand for RYK in glioma cells to stimulate the expression of MMP2 and the invasive behavior through beta-catenin-independent pathways. This signal mechanism has an impact on malignant glioma prognosis and opens the way to the identification of effective therapeutic targets. 27 RYK plays also a role in maintenance of stemness of glioblastoma cancer stem cells (GSCs) as has been demonstrated testing RYK mRNA expression in patient-derived GSC lines with different degree of differentiation. RYK was expressed at a much greater extent in poor differentiated than in better differentiated GSCs cells and promoted neurosphere formation enhancing anchorage-independent cell growth and cell migration. In this case RYK shows the ability to establish and maintain an undifferentiated cell state trough beta-catenin signal pathway. 28,Entity name: Gastric cancer RYK expression analysis in human gastric cancer samples and in GC (gastric cancer) cell lines shows high correlation between RYK-mRNA levels and metastatic potential. There is also a strong correlation with the expression levels of EMT (epithelial mesenchymal transition) markers that characterize tumorigenesis. Moreover RYK knockdown impairs migration, invasion and EMT of GC cells in vitro and abolishes tumorigenesis and metastasization of GC cells in a xenograft rodent model. Consistently RYK expression is negatively correlated with E-cadherin and positively correlated with N-cadherin, as you might expect considering that the E-cadherin to N-cadherin switch is essential in the progression of cancer. RYK protein expression in cancer cell lines follows the same trend as mRNA. Inhibition of canonical Wnt pathway component beta-catenin fails to antagonize the RYK-induced metastasis phenotypes. This result, together with the fact that WNT5A too is highly correlated with RYK expression suggests that prometastasis effect of RYK in GC might be mediated, at least partially, by the noncanonical Wnt signaling pathway. 29,Entity name: Malignant melanoma Many melanomas (50%) harbor BRAF gene mutation (BRAFV600E/K) and the BRAF inhibitors (BRAFis) treatment is clinically effective in a non-lasting way. A subset of tumors that develop drug resistance and relapse shows very elevated WNT5A transcript and protein. The same is true for therapy-resistant melanoma cell lines treated in vitro with BRAFis. Overexpression of WNT5A promotes melanoma growth, tumorigenesis, and activation of prosurvival AKT signaling. WNT5A promotes the growth and survival of both naive parental cells and BRAFis-resistant melanoma cells. WNT5A knockdown, as well as knockdown of the WNT receptors FZD7 and RYK inhibits growth, sensitizes melanoma cells to BRAFis, and reduces AKT activation phosphorylation-mediated.Therefore WNT5A promotes melanoma growth and survival via its receptors RYK and FZD7. The WNT5A receptors FZD7 and RYK are highly expressed in melanoma with a difference between them: FZD7 is highly expressed in both normal skin and melanoma while RYK is overexpressed only in melanoma. SiRNAs targeting the WNT receptors FZD4, FZD5, FZD7, and RYK reduce melanoma cell viability and growth. Cells with overexpressed WNT5A may represent a distinct cellular phenotype that can be either induced or enriched by long-term BRAFis treatment. BRAFis-resistant melanoma cells often exhibit cross-resistance to other BRAF/MAPK pathway inhibitors. A significant correlation between WNT5A expression and survival has not been found in the small cohort of 11 patients analyzed in the study 30. Inhibiting this WNT5A/RYK/FZD7 pathway might be therapeutically beneficial in melanoma patients who have developed resistance to BRAF/MAPK– targeted therapies.,Entity name: Prostate carcinoma WNT5A has an antitumor effect on prostate cancer cells in vitro. Receptors FZD5 and RYK mediate the effects of WNT5A. RYK knock-down inhibits the pro-apoptotic effect of WNT5A in cancer cells by 60% while the opposite happens knocking down FZD5. mRNA and protein expression of RYK is increased in advanced prostate cancer tumor stages. However, its expression is not associated with the survival of prostate cancer patients. Interestingly nuclear RYK (RIK ICD or RIK intracellular domain) shows an opposite expression pattern. This underlines the importance of distinguishing between the cleavage products of RYK and points out how difficult is to reach linear conclusions in a field in which intricate networks of signals and very delicate modulation phenomena hide the main events 31.

Bibliography

Reference NumberPubmed IDLast YearTitleAuthors

Citation

Roberto Brusamolino ; Alessandro Beghini

RYK

Atlas Genet Cytogenet Oncol Haematol. 2022-03-18

Online version: http://atlasgeneticsoncology.org/gene/209165/ryk